Science News
from research organizations

More GI bleeding seen in atrial fibrillation patients on rivaroxaban than warfarin

Date:
October 22, 2012
Source:
American College of Chest Physicians
Summary:
Patients with atrial fibrillation experienced more major and non-major clinically relevant GI bleeding when taking rivaroxaban than patients taking warfarin.
Share:
       
FULL STORY

Patients with atrial fibrillation (AF) experienced more major and non-major clinically relevant GI bleeding when taking rivaroxaban than patients taking warfarin.

As part of the ROCKET AF trial, researchers from multiple institutions, including Harvard Medical School; Mount Sinai Medical Center; Janssen Research & Development; and Bayer HealthCare Pharmaceuticals, randomized 14,264 patients with nonvalvular AF to receive either rivaroxaban or dose-adjusted warfarin. Post-hoc analysis was performed on all patients while receiving study medication until 2 days after the last dose.

Results showed that GI bleeding events (upper, lower, rectal) occurred more frequently in patients receiving rivaroxaban (n=394) than warfarin (n=290). In addition, major and nonmajor, clinically relevant bleeding occurred more frequently with rivaroxaban use than warfarin use. However, there were fewer fatal GI bleeds with rivaroxaban and the absolute fatality rate was very low.

This study was presented during CHEST 2012, the annual meeting of the American College of Chest Physicians, held October 20 -- 25, in Atlanta, Georgia.


Story Source:

The above post is reprinted from materials provided by American College of Chest Physicians. Note: Materials may be edited for content and length.


Cite This Page:

American College of Chest Physicians. "More GI bleeding seen in atrial fibrillation patients on rivaroxaban than warfarin." ScienceDaily. ScienceDaily, 22 October 2012. <www.sciencedaily.com/releases/2012/10/121022081021.htm>.
American College of Chest Physicians. (2012, October 22). More GI bleeding seen in atrial fibrillation patients on rivaroxaban than warfarin. ScienceDaily. Retrieved July 5, 2015 from www.sciencedaily.com/releases/2012/10/121022081021.htm
American College of Chest Physicians. "More GI bleeding seen in atrial fibrillation patients on rivaroxaban than warfarin." ScienceDaily. www.sciencedaily.com/releases/2012/10/121022081021.htm (accessed July 5, 2015).

Share This Page: